The Future of Biomarkers in Prostate Cancer

Ravindra Uppaluri, MD, PhD, discussed the KEYNOTE-689 trial, which investigated pembrolizumab in locally advanced head and neck squamous cell carcinoma.

Adam Weiner, MD, discusses his journey toward becoming an oncologist with a focus in urology in this episode of Emerging Experts.

Prostatectomy for grade group 1 prostate cancer significantly decreased from 2010 to 2024 in SEER and MUSIC data. Remaining cases show more high-risk features.

In this episode of Emerging Experts, Nazli Dizman, MD, shares the intricacies of her journey towards becoming an oncologist in the United States.

The EMBARK analysis showed most men regained testosterone after stopping enzalutamide/leuprolide or placebo/leuprolide for prostate cancer with good PSA response, and recovery was common across age groups.

In an interview, Stacy Loeb, MD, discussed a study analyzing prostate cancer misinformation on social media.